A protest in Ireland calls on the Health Service Executive (HSE) to make Skyclarys available for reimbursement to patients with Friedreich’s ataxia. Emily Felix is reported to be among those leading the campaign, urging decision-makers to “think past price” in evaluating access to the treatment. The concern centres on whether patients can obtain the drug through the health system rather than paying privately.
The outlets describe the campaign as focused on reimbursement and broader affordability, rather than questioning the need for treatment. Protesters and supporters argue that the cost should be weighed against potential benefits for people living with the rare inherited condition. The message is that pricing considerations should not prevent patients from accessing Skyclarys.
Overall, the reporting aligns on the existence of a public push directed at the HSE and the central demand that Skyclarys be reimbursed for Friedreich’s ataxia patients in Ireland.
